Cataract | Ophthalmology Innovation Source

Mynosys Cellular Devices

Zepto is an innovative disposable device, used in cataract surgery that uses precision pulse technology. The company notes the device is accurate and creates a reproducible capsulotomy that is quick, safe, and affordable. Zepto consists of a silicon suction cup, a nitinol capsulotomy cutting element and an incision finder/push-rod system. The system works by stretching…

PowerVision

PowerVision has developed “the first true shape-changing, fluid driven intraocular lens (IOL),” CEO Barry Cheskin said. The FluidVision IOL creates a “continuously variable monofocal” where no light is split as is currently the case with multifocal lenses. The lens mimics the eye’s natural accommodative power to transport fluids inside it, which creates the shape change.…

Ocular Therapeutix

The company is evaluating sustained-release injectable anti-VEGF drug depots along with use of its proprietary hydrogel platform technology for anterior segment disorders (specifically pain and inflammation). Ocular Therapeutix’s OTX drug-eluting punctal plug is a non-invasive procedure that will eliminate drops (and the potential non-compliance). During the past year, the company completed two of three planned…

Looking Deep at Extended Depth-of-Focus IOLs

Multifocal IOLs, perhaps the best established solution to the problem of enabling post-cataract patients to see clearly at all distances, work by incorporating discrete refractive optical zones or diffractive echelettes into the lens. Accommodating IOLs, which aim to provide the same benefit, use ciliary muscle power to move the lens and/or change its shape to…

Is Auris Still Building a Robot for Cataract Surgery?

Auris Surgical Robotics Inc., a Bay Area medical technology company that had been developing a robotic platform for cataract surgery, just raised $150 million, but is in “stealth” mode as to what the proceeds of the capital infusion will be used for. David Schumer, head of marketing for Auris, would neither confirm nor deny reports…

Premium IOLs: Two Outliers with Mainstream Potential

A problem that plagues refractive cataract surgery is the difficulty of determining the IOL power that will achieve each patient’s refractive target. In the old days, if a post-cataract patient wasn’t satisfied with their vision, they simply wore a pair of glasses. But patients paying thousands of dollars for a premium IOL are not satisfied…

A Look at Premium IOLs

Can Accommodating IOLs Fuel Demand? For nearly two decades, “presbyopia-correcting” intraocular lenses (IOLs) have been available to post-cataract surgery patients, but for a variety of reasons they have garnered only modest interest. According to Market Scope, presbyopia-correcting lenses only account for 2.4% of total IOLs implanted globally in 2014. Moreover, use of these IOLs has…

ClarVista’s Two-Part Strategy To Premium IOLs

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 053″] CEO Paul McLean and Medical Director Malik Kahook, MD, explain how they’ll bring Harmoni to the IOL market. Podcast Guest Paul McLean Paul McLean is President and CEO of ClarVista Medical. ClarVista Medical is clinical stage, ophthalmic device Start-up Company focused on the development of the HARMONI modular intra-ocular lens…

Calhoun Vision Stages Turnaround

Medtech companies in ophthalmology have made some significant strides in recent months. Second Sight and Glaukos, of course, staged IPOs in their pursuit of revolutionary ophthalmic devices. Oculeve excited Dry Eye leader Allergan enough to warrant a significant acquisition offer, bringing the highly promising neurostim device in-house where it may someday complement Restasis. Now we’re…

Hear Bausch + Lomb’s Ophthalmology Play Book

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 046″] Bausch + Lomb Surgical’s Andrew Chang Has Big Plans in Ophthalmology Surgical. Podcast Guest Andrew Chang Andrew is the General Manager and Vice President of US Surgical for Bausch + Lomb, a subsidiary of Valeant International. Prior to joining B+L/Valeant, Andrew was the Director of Marketing for OptiMedica/Catalys before it…

Hear How Valeant Innovates, Invests & Acquires

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 043″] Valeant CEO J. Michael Pearson tells OIS attendees how the controversial company finds new technologies. Podcast Guest J. Michael Pearson Mr. Pearson has been the CEO and serving on the Board since September 2010 and the Chairman of the Board since March 2011. From February 2008 to September 2010, he…

Spotlight on Presbyopia – Market Overview

Participant: Richard Lindstrom, MD Dr. Lindstrom is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery. View Full Profile